Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC): Final results of the Phase 1/2 and Phase 2 (ALTA) trials

R. Huber; S. Gettinger; D. -W Kim; L. Bazhenova; K. Hansen; M. Tiseo; C. Langer; L. Paz-Ares Rodriguez; H. West; K. Reckamp; G. Weiss; E. Smit; M. Hochmair; S. -W Kim; M. -J Ahn; E. Kim; H. Groen; J. Pye; F. Vranceanu; D. R. Camidge

Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC): Final results of the Phase 1/2 and Phase 2 (ALTA) trials

R. Huber, S. Gettinger, D. -W Kim, L. Bazhenova, K. Hansen, M. Tiseo, C. Langer, L. Paz-Ares Rodriguez, H. West, K. Reckamp, G. Weiss, E. Smit, M. Hochmair, S. -W Kim, M. -J Ahn, E. Kim, H. Groen, J. Pye, F. Vranceanu, D. R. Camidge

Onderzoeksoutput › Academic

Originele taal-2	English
Pagina's (van-tot)	4-5
Aantal pagina's	2
Tijdschrift	Oncology Research and Treatment
Volume	44
Status	Published - sep.-2021

Handle.net

Permanente koppeling

Citeer dit

Huber, R., Gettinger, S., Kim, D. -W., Bazhenova, L., Hansen, K., Tiseo, M., Langer, C., Paz-Ares Rodriguez, L., West, H., Reckamp, K., Weiss, G., Smit, E., Hochmair, M., Kim, S. -W., Ahn, M. -J., Kim, E., Groen, H., Pye, J., Vranceanu, F., & Camidge, D. R. (2021). Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC): Final results of the Phase 1/2 and Phase 2 (ALTA) trials. Oncology Research and Treatment, 44, 4-5.

@article{a72dd058dd3b417e961c8cac5d4d93b6,

title = "Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC): Final results of the Phase 1/2 and Phase 2 (ALTA) trials",

author = "R. Huber and S. Gettinger and Kim, {D. -W} and L. Bazhenova and K. Hansen and M. Tiseo and C. Langer and {Paz-Ares Rodriguez}, L. and H. West and K. Reckamp and G. Weiss and E. Smit and M. Hochmair and Kim, {S. -W} and Ahn, {M. -J} and E. Kim and H. Groen and J. Pye and F. Vranceanu and Camidge, {D. R.}",

year = "2021",

month = sep,

language = "English",

volume = "44",

pages = "4--5",

journal = "Oncology Research and Treatment",

issn = "2296-5270",

publisher = "KARGER",

}

Huber, R, Gettinger, S, Kim, D-W, Bazhenova, L, Hansen, K, Tiseo, M, Langer, C, Paz-Ares Rodriguez, L, West, H, Reckamp, K, Weiss, G, Smit, E, Hochmair, M, Kim, S-W, Ahn, M-J, Kim, E, Groen, H, Pye, J, Vranceanu, F & Camidge, DR 2021, 'Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC): Final results of the Phase 1/2 and Phase 2 (ALTA) trials', Oncology Research and Treatment, vol. 44, blz. 4-5.

TY - JOUR

T1 - Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC)

T2 - Final results of the Phase 1/2 and Phase 2 (ALTA) trials

AU - Huber, R.

AU - Gettinger, S.

AU - Kim, D. -W

AU - Bazhenova, L.

AU - Hansen, K.

AU - Tiseo, M.

AU - Langer, C.

AU - Paz-Ares Rodriguez, L.

AU - West, H.

AU - Reckamp, K.

AU - Weiss, G.

AU - Smit, E.

AU - Hochmair, M.

AU - Kim, S. -W

AU - Ahn, M. -J

AU - Kim, E.

AU - Groen, H.

AU - Pye, J.

AU - Vranceanu, F.

AU - Camidge, D. R.

PY - 2021/9

Y1 - 2021/9

M3 - Meeting Abstract

VL - 44

SP - 4

EP - 5

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

SN - 2296-5270

ER -